001     132793
005     20240229105032.0
024 7 _ |a 10.1186/s13058-018-0955-5
|2 doi
024 7 _ |a pmid:29665866
|2 pmid
024 7 _ |a pmc:PMC5905156
|2 pmc
024 7 _ |a 1465-5411
|2 ISSN
024 7 _ |a 1465-542X
|2 ISSN
024 7 _ |a altmetric:38220183
|2 altmetric
037 _ _ |a DKFZ-2018-00437
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Campa, Daniele
|b 0
245 _ _ |a Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
260 _ _ |a London
|c 2018
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1525781719_9511
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Leukocyte telomere length (LTL) and mitochondrial genome (mtDNA) copy number and deletions have been proposed as risk markers for various cancer types, including breast cancer (BC).To gain a more comprehensive picture on how these markers can modulate BC risk, alone or in conjunction, we performed simultaneous measurements of LTL and mtDNA copy number in up to 570 BC cases and 538 controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. As a first step, we measured LTL and mtDNA copy number in 96 individuals for which a blood sample had been collected twice with an interval of 15 years.According to the intraclass correlation (ICC), we found very good stability over the time period for both measurements, with ICCs of 0.63 for LTL and 0.60 for mtDNA copy number. In the analysis of the entire study sample, we observed that longer LTL was strongly associated with increased risk of BC (OR 2.71, 95% CI 1.58-4.65, p = 3.07 × 10- 4 for highest vs. lowest quartile; OR 3.20, 95% CI 1.57-6.55, p = 1.41 × 10- 3 as a continuous variable). We did not find any association between mtDNA copy number and BC risk; however, when considering only the functional copies, we observed an increased risk of developing estrogen receptor-positive BC (OR 2.47, 95% CI 1.05-5.80, p = 0.04 for highest vs. lowest quartile).We observed a very good correlation between the markers over a period of 15 years. We confirm a role of LTL in BC carcinogenesis and suggest an effect of mtDNA copy number on BC risk.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Barrdahl, Myrto
|0 P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63
|b 1
|u dkfz
700 1 _ |a Santoro, Aurelia
|b 2
700 1 _ |a Severi, Gianluca
|b 3
700 1 _ |a Baglietto, Laura
|b 4
700 1 _ |a Omichessan, Hanane
|b 5
700 1 _ |a Tumino, Rosario
|b 6
700 1 _ |a Bueno-de-Mesquita, H B As
|b 7
700 1 _ |a Peeters, Petra H
|b 8
700 1 _ |a Weiderpass, Elisabete
|b 9
700 1 _ |a Chirlaque, Maria-Dolores
|b 10
700 1 _ |a Rodríguez-Barranco, Miguel
|b 11
700 1 _ |a Agudo, Antonio
|b 12
700 1 _ |a Gunter, Marc
|b 13
700 1 _ |a Dossus, Laure
|b 14
700 1 _ |a Krogh, Vittorio
|b 15
700 1 _ |a Matullo, Giuseppe
|b 16
700 1 _ |a Trichopoulou, Antonia
|b 17
700 1 _ |a Travis, Ruth C
|b 18
700 1 _ |a Canzian, Federico
|0 P:(DE-He78)5323704270b6393dcea70186ffd86bca
|b 19
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 20
|e Last author
|u dkfz
773 _ _ |a 10.1186/s13058-018-0955-5
|g Vol. 20, no. 1, p. 29
|0 PERI:(DE-600)2041618-0
|n 1
|p 29
|t Breast cancer research
|v 20
|y 2018
|x 1465-542X
909 C O |o oai:inrepo02.dkfz.de:132793
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)5323704270b6393dcea70186ffd86bca
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BREAST CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BREAST CANCER RES : 2015
920 1 _ |0 I:(DE-He78)C055-20160331
|k C055
|l Genomische Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C055-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21